FDA reported last week that it has approved the application for expanded indications for cardiac resynchronization therapy/defibrillation (CRT-D) by Boston Scientific (BSX; Natick Massachusetts), an approval the company invested millions to win. If one uses the outcome of an advisory committee hearing as the starting point, BSX had to wait six months to gain FDA's approval, which applies to three of its CRT-D units, but the euphoria is likely to be short lived as the company must now wrestle with reimbursement issues. (Medical Device Daily) Read More
